However, the use of LPV/RTV plus IFN combination resulted in fewer therapeutic responses on COVID-19 in terms of viral clearance [median (interquartile range, IQR), 4 (2.5–9) d versus 11 (8–13) d, p < 0.001) and chest CT changes (91.43% vs. 62.22%), p = 0.004] compared to the favipiravir plus IFN combination. Here, IFNA1 is linked to COVID-19.